Policy & Regulation
Endra Life Sciences Expands Pharmaceutical Partnerships with VGI Health Technology
29 November 2021 - - US-based Endra Life Sciences Inc. (NASDAQ: NDRA), a developer of Thermo Acoustic Enhanced UltraSound (TAEUS) technology, and Australia-based biotechnology company VGI Health Technology Ltd. (NSX: VTL), have signed a collaboration agreement to incorporate Endra's proprietary TAEUS technology to support patient screening and biomarker measurement during VGI's upcoming Phase 2 study of IVB001 in Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis, the companies said.

In September 2015 a Phase 1a clinical study with IVB001 met all primary endpoints including confirmation of the bioavailability of the compound with good plasma levels, dose relationship and duration of plasma levels achieved.

Research from a number of groups using orally delivered tocotrienols to treat NAFLD-NASH have shown promising results in improving liver function and bringing about favorable histological changes in NAFLD-NASH.

This points to transmucosally delivered tocotrienols like VGI's IVB001 having great potential to address this intractable disease where there is no approved treatment.

VGI Health Technology Ltd. (NSX: VTL) is an Australian biotechnology company developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis, pancreatic cancer, hyperlipidaemia, hypertension and diabetes.

VTL owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues.

The company has a clinical development program for prescription medicines and a product development program for evidence-based nutraceuticals.

Endra Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS), a technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care.

TAEUS is designed to work in concert with 400,000 cart-based ultrasound systems in use globally TODAY.

TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis, chronic liver conditions that affect over one bn people globally, and for which there are no practical diagnostic tools.

Beyond the liver, Endra is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.


Related Headlines